Zeller T
Department of Angiology, Heart Center Bad Krozingen, Bad Krozingen, Germany.
Minerva Cardioangiol. 2007 Feb;55(1):115-23.
Renal artery stenosis (RAS) may cause or deteriorate arterial hypertension and/or renal insufficiency. Moreover, RAS seems to affect structural heart disease. Technical improvements of diagnostic and interventional endovascular tools have led to a more widespread use of endoluminal renal artery revascularization and extension of the indications for this type of therapy. Since the first renal artery angioplasties performed by Mahler and Grüntzig in 1978, mostly single center studies have reported in the majority of patients beneficial effects of percutaneous transluminal renal angioplasty, and since the early 1990's of stenting RAS. Due to reports upon post procedural impairment of renal function in a reasonable number of patients, the role of protection devices has been raised recently. This article summarizes the current technique of endovascular treatment of RAS and the clinical impact on blood pressure control, renal function, and structural heart disease. The results discussed are based mainly on registry data because randomized studies comparing stent-supported angioplasty with best medical therapy are still missing.
肾动脉狭窄(RAS)可能导致或加重动脉高血压和/或肾功能不全。此外,RAS似乎会影响结构性心脏病。诊断和介入性血管内工具的技术改进使得腔内肾动脉血运重建的应用更为广泛,且此类治疗的适应症也有所扩展。自1978年马勒(Mahler)和格鲁恩齐格(Grüntzig)首次进行肾动脉血管成形术以来,大多数单中心研究报告称,在大多数患者中经皮腔内肾血管成形术具有有益效果,自20世纪90年代初开始对RAS进行支架置入术。由于有报道称相当数量的患者术后肾功能受损,保护装置的作用最近受到了关注。本文总结了RAS血管内治疗的当前技术以及对血压控制、肾功能和结构性心脏病的临床影响。所讨论的结果主要基于登记数据,因为比较支架置入血管成形术与最佳药物治疗的随机研究仍然缺乏。